This has already been documented in patients with metastatic prostate cancer harboring a germline pathogenic variant in ATM sensitizing to PARP inhibition, as well as in patients with pancreatic cancer where monoallelic pathogenic variants in ATM produce susceptibility to combined therapies that synergistically target the DNA-damage response pathway (51, 52). Here, ATM is linked to metastatic prostate carcinoma.